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BRIEF COMMUNICATION
THE USE OF THE ANTIFUNGAL AGENT MICONAZOLE AS AN INHIBITOR OF Blastocystis hominis
GROWTH IN Entamoeba histolytica/E. dispar CULTURES
Alessandra Queiroga GONÇALVES(1), João da Costa VIANA(2), Edna Maria PIRES(2), Márcio Neves BÓIA(1), José Rodrigues COURA(1) & Edward Félix SILVA(2)
SUMMARY
In regions with high prevalence, Blastocystis hominis is frequently found in association with Entamoeba histolytica/E. dispar
in xenic cultures. Its exacerbated growth is often superimposed on the growth of amebas, thus impeding the continuation of the
amebas in the culture, within a few generations. The present study reports on the excellent efficacy (100%) of the antifungal agent
miconazole in eliminating B. hominis from cultures of E. histolytica/E. dispar, thereby maintaining the integrity of the trophozoites
of the amebas. Nystatin presented low efficacy (33.3%).
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The human intestinal protozoan Blastocystis hominis causes
infection that is often asymptomatic, and is found at higher prevalence
in developing countries1. Although it is one of the most common
parasites encountered in stool samples, its pathogenicity is still
controversial4. In regions of high endemicity, B. hominis is frequently
found in xenic cultures of Entamoeba histolytica/E. dispar. In cultures
it tends to grow vigorously and, unless it is eradicated completely at
an early stage, it eventually overgrows and kills all amebas, usually
within a few generations3,7.
There are some methods for eliminating B. hominis from ameba
cultures. DOBELL & LAIDLAW3 described ameba cyst treatment with
a 0.2% solution of hydrochloric acid, at room temperature, for two
hours (or with 0.1 N HCl for 10 minutes, according to CLARK &
DIAMOND2), followed by washing with distilled water and
reinoculation into a culture medium to which a suitable bacterial flora
has been added. The acid kills B. hominis, fungi and bacteria, while
leaving the cysts intact. In the method described by SMEDLEY7, ameba
cultures are pelleted, resuspended in distilled water at room temperature
for 20 minutes, repelleted, and then this material is inoculated into
fresh culture medium. This last procedure is simple, and it is not
necessary to use separate bacterial flora. However, it needs to be
repeated a couple of times before the B. hominis is completely
eliminated2. The use of acriflavin (with or without subsequent passage
through a medium containing lactic acid) for decontaminating the
cultures is generally unsatisfactory, presenting adverse effects on the
bacterial flora and, directly or indirectly, on the amebas2,3,7,8. According
to SILVA6, culture treatment with nystatin at 25-50 UI/mL
concentrations does not present high efficacy in decontamination, and
B. hominis resistance to nystatin occurs in some cases.
This study reports on the excellent inhibitory action of the antifungal
agent miconazole on B. hominis found in cultures of amebas, thereby
keeping the amebas alive. It was approved by protocol number 217/
03, from the ethical committee of Oswaldo Cruz Foundation.
Twenty fresh stool samples (from people living in the municipality
of Barcelos, Amazonas State, Brazil) containing cysts of E. histolytica/
E. dispar were inoculated into tubes containing 10 mL of modified
Pavlova medium for polyxenic culturing5. The cultures were maintained
at 37 ºC, undergoing passage through this medium every 48 hours.
Cultures positive for both amebas and B. hominis were treated with
nystatin (Cristália, oral suspension), acriflavin (Difco Laboratories)
and miconazole (miconazole nitrate, Teuto, skin lotion 2%), with the
aim of eliminating the B. hominis. Firstly, treatment was applied using
nystatin alone. This was followed by using acriflavin with nystatin in
cultures that had not been decontaminated with the previous scheme.
Lastly, miconazole was used against resistant B. hominis.
Out of 20 cultures, 18 presented B. hominis in association with
amebas. During treatment with nystatin, two ameba cultures were lost
because of high contamination by B. hominis. Among the remaining
16 cultures, decontamination was achieved for six of them after 2-5
treatments with nystatin at final concentrations of 25-75 UI/mL. Among
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the 10 cultures that were not freed of B. hominis, eight underwent
treatment with nystatin and acriflavin at varying concentrations.
Decontamination was not achieved via this procedure. Subsequently,
they underwent miconazole treatment at final concentrations of 10-40
µg/mL, and this led to B. hominis elimination in all of these eight
ameba cultures, after a maximum of three passages with this drug.
To evaluate the effect of miconazole alone, without interference
from any other drug, we conducted this treatment procedure on two
further ameba cultures. One culture was completely decontaminated
after two consecutive passages, with 40 and 20 µg/mL of miconazole,
respectively. For the other one, treatment was effective with just a
single passage at 20 µg/mL (Table 1).
In the present study, 100% efficacy (10/10) was obtained in
eliminating the stages of B. hominis. Nystatin is currently used in the
Amebiasis Laboratory of ICB/UFMG for decontaminating E. histolytica/
E. dispar cultures in relation to B. hominis. However, its low yield for
this purpose has already been noted previously6. In the present study,
nystatin also demonstrated low efficacy, of 33.3% (6/18).
Due the high efficacy of miconazole in eliminating B. hominis,
without reducing the quality of ameba trophozoites, we suggest the
standardization of culturing treatments by means of the use of
miconazole at a final concentration of 40 µg/mL, followed by
reinforcement of the treatment in a second passage, at 20 µg/mL.
The excellent in vitro action of miconazole against the protozoan
B. hominis brings the prospect that it could be routinely used in
laboratories that isolate Entamoeba species from stools, thereby
reducing problems such as loss of cultures. This procedure was shown
to be effective, rapid and easy to perform. One further advantage was
that treatment could be carried out directly in established polyxenic
cultures, without ameba cell manipulation.
RESUMO
Uso do antifúngico miconazol como inibidor do crescimento de
Blastocystis hominis em culturas de Entamoeba histolytica/E.
dispar
Em regiões de alta prevalência, Blastocystis hominis é freqüen-
temente encontrado em associação com Entamoeba histolytica/E.
dispar em cultivos xênicos. Seu crescimento exacerbado se sobrepõe
muitas vezes ao das amebas, impedindo a manutenção destas em
cultura, dentro de poucas gerações. O presente estudo relata a excelente
eficácia (100%) do antifúngico miconazol na eliminação de B. hominis
dos cultivos de E. histolytica/E. dispar, mantendo-se a integridade dos
trofozoítos das amebas. A nistatina apresentou eficácia baixa (33,3%).
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Table 1
Efficacy of drugs against B. hominis present in 18 ameba cultures
Drugs No. of cultures decontaminated/
No. of cultures undergoing treatment (%)
Nystatin 6/18 (33.3%)
Nystatin + Acriflavin 0/8 (0%)
Miconazole 10/10 (100%)
